HIGH IMPACT - Surface Oncology provided a corporate update, including the decision to pause internal clinical development of SRF617 (CD39 mAb) and early clinical data for SRF388 monotherapy in NSCLC. The company intends to open a SRF388 + pembrolizumab…
https://inthought.com/wp-content/uploads/2022/03/blank-transparent.png720720old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2022-11-02 00:00:412022-12-05 17:39:40Surface Oncology pauses development and seeks business partner for its CD39 mAb; attempts to shift focus to positive NSCLC data for SRF388 (IL-27 mAb) and development of SRF144 (CCR8 mAb)
HIGH IMPACT - Travere hosted a call to discuss the recent regulatory update for sparsentan Travere’s sparsentan was previously assigned a PDUFA target action date of November 17, 2022 for its NDA under accelerated approval for the treatment…
HIGH IMPACT - Wave Life Sciences hosted an investor call titled “Towards the Clinic: Spotlight on RNA Editing for AATD” to discuss their technology, preclinical results, and path forward for WVE-006, their mRNA editing treatment for patients…
https://inthought.com/wp-content/uploads/2022/03/blank-transparent.png720720old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2022-09-28 00:00:432022-10-06 23:04:43Wave Life Sciences bolsters ASO potential for the treatment of A1ATD during investor call for WVE-006
HIGH IMPACT - In an SEC filing, BioMarin disclosed that they were notified on August 19th, 2022 that a participant in the Roctavian Phase 3 trial was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). Based on BioMarin’s assessment…
https://inthought.com/wp-content/uploads/2022/03/blank-transparent.png720720old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2022-09-12 00:00:272022-10-06 22:57:15BioMarin Discloses Report of Cancer in Roctavian Phase 3 Trial
HIGH IMPACT - Iveric Bio announced topline data from GATHER2, its second phase 3 study of C5 aptamer, Zimura (Avacincaptad pegol) in geographic atrophy. Efficacy (anatomical): 14.3% reduction in mean rate of GA growth (slope; mm) at…
https://inthought.com/wp-content/uploads/2022/03/blank-transparent.png720720old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2022-09-06 00:00:572022-10-06 22:54:06Iveric Bio's second phase 3 study of Zimura meets primary endpoint in geographic atrophy
HIGH IMPACT - The European Commission (EC) has granted conditional marketing authorization (CMA) to ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A in adults without Factor VIII inhibitors and without…